Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility
- 16 May 2014
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 65 (2) , 252-260
Abstract
Aims: To compare SP6 and MIB1 antibodies for assessment of Ki67 in primary breast cancer with regard to prognostic value and reproducibility.Methods and results: A cohort of 237 premenopausal women with node‐negative breast cancer, mainly (87%) not treated with adjuvant systemic therapy, was used. Assessment of Ki67 (SP6 and MIB1) was performed on tissue microarray by three different investigators. The seventh decile was applied for cut‐off. Distant disease‐free survival (DDFS) was chosen as endpoint and the follow‐up was restricted to 5 years. Eighty‐nine per cent of the samples were classified into the same proliferation group, irrespective of antibody used. For both antibodies, high Ki67 was associated with inferior DDFS in univariable analyses (SP6: HR 2.5, P = 0.01; and MIB1: HR 2.8, P = 0.004), but failed to reach statistical significance for DDFS in multivariable analyses adjusted for HER2, age, and tumour size (SP6: HR 2.0, P = 0.074; and MIB1: HR 2.2, P = 0.058). The agreement between different assessors was somewhat higher for MIB1 than for SP6 (κ 0.83–0.88 versus 0.72–0.77).Conclusions: SP6 was not superior to MIB1, but the two antibodies were comparable in the assessment of Ki67. Both MIB1 and SP6 could therefore be considered for prognostic use in primary breast cancer.Keywords
Funding Information
- Anna and Edwin Berger Foundation
- Futurum - the Academy of Health and Care, J�nk�ping County Council
- Governmental funding of clinical research within the Swedish National Health Service
- Gunnar Nilsson Cancer Foundation
- Mrs Berta Kamprad Foundation
- Swedish Cancer Society
- Swedish Research Council
This publication has 22 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and GynecopathologistsPLOS ONE, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Comparative validation of the SP6 antibody to Ki67 in breast cancerJournal of Clinical Pathology, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancerLaboratory Investigation, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991